PMID- 34231261 OWN - NLM STAT- MEDLINE DCOM- 20210930 LR - 20220720 IS - 1939-1676 (Electronic) IS - 0891-6640 (Print) IS - 0891-6640 (Linking) VI - 35 IP - 5 DP - 2021 Sep TI - A retrospective study of adverse effects of mycophenolate mofetil administration to dogs with immune-mediated disease. PG - 2215-2221 LID - 10.1111/jvim.16209 [doi] AB - BACKGROUND: Information regarding adverse events (AEs) of mycophenolate mofetil (MMF) is limited. OBJECTIVES: To evaluate the types and frequency of potential AEs of MMF in dogs with immune-mediated disease. ANIMALS: One hundred thirty-one dogs treated with MMF for management of suspected immune-mediated disease. METHODS: Retrospective study. Medical records were reviewed to find and group suspect AEs in gastrointestinal (GI), hematologic, and other categories. Age, dosage, body weight, and sex were analyzed between dogs with and without AEs by using the Mann-Whitney U-test and chi-squared test. RESULTS: The median starting dosage of MMF was 17.5 mg/kg/day (interquartile range [IQR] = 15.1-20.6 mg/kg/day) and the median treatment duration was 56 days (IQR = 14-236 days). Mycophenolate mofetil was prescribed for immune-mediated hemolytic anemia (n = 31), immune-mediated thrombocytopenia (n = 31), pemphigus foliaceus (n = 15), immune-mediated polyarthritis (n = 12), and others (n = 42). Overall, potential AEs of MMF were observed in 34 of 131 dogs (GI 24.4% [31/127], neutropenia 4% [3/76], anemia 4% [1/25], thrombocytopenia 4.0% [1/25], and dermatologic 1.5% [2/131]). There were no significant differences among dogs with (n = 37) or without potential AEs (n = 94) in regards to sex, age, body weight, or dosage of MMF (P = .06, .13, .24, and .26, respectively). CONCLUSIONS AND CLINICAL IMPORTANCE: In the dogs administered MMF, GI AEs were most common. Since potential hematologic and dermatologic AEs developed in a few dogs, clinicians should be aware of these when prescribing MMF to dogs with immune-mediated disease. CI - (c) 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine. FAU - Fukushima, Kenjiro AU - Fukushima K AUID- ORCID: 0000-0003-4271-8267 AD - Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado, USA. FAU - Lappin, Michael AU - Lappin M AUID- ORCID: 0000-0003-1605-9667 AD - Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado, USA. FAU - Legare, Marie AU - Legare M AD - Department of Environmental and Radiological Health Science, Colorado State University, Fort Collins, Colorado, USA. FAU - Veir, Julia AU - Veir J AD - Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado, USA. LA - eng PT - Journal Article DEP - 20210706 PL - United States TA - J Vet Intern Med JT - Journal of veterinary internal medicine JID - 8708660 RN - 0 (Immunosuppressive Agents) RN - HU9DX48N0T (Mycophenolic Acid) SB - IM EIN - J Vet Intern Med. 2022 Sep;36(5):1844. PMID: 35856626 MH - *Anemia, Hemolytic, Autoimmune/veterinary MH - Animals MH - *Dog Diseases/chemically induced/drug therapy MH - Dogs MH - Immunosuppressive Agents/adverse effects MH - Mycophenolic Acid/adverse effects MH - Retrospective Studies MH - *Thrombocytopenia/veterinary PMC - PMC8478029 OTO - NOTNLM OT - adverse events OT - canine OT - immunosuppressant OT - toxicity COIS- Authors declare no conflict of interest. EDAT- 2021/07/08 06:00 MHDA- 2021/10/01 06:00 PMCR- 2021/09/01 CRDT- 2021/07/07 07:16 PHST- 2021/06/11 00:00 [revised] PHST- 2020/06/29 00:00 [received] PHST- 2021/06/18 00:00 [accepted] PHST- 2021/07/08 06:00 [pubmed] PHST- 2021/10/01 06:00 [medline] PHST- 2021/07/07 07:16 [entrez] PHST- 2021/09/01 00:00 [pmc-release] AID - JVIM16209 [pii] AID - 10.1111/jvim.16209 [doi] PST - ppublish SO - J Vet Intern Med. 2021 Sep;35(5):2215-2221. doi: 10.1111/jvim.16209. Epub 2021 Jul 6.